Nathan C. Ihle

1.2k total citations
21 papers, 959 citations indexed

About

Nathan C. Ihle is a scholar working on Oncology, Organic Chemistry and Molecular Biology. According to data from OpenAlex, Nathan C. Ihle has authored 21 papers receiving a total of 959 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Oncology, 6 papers in Organic Chemistry and 5 papers in Molecular Biology. Recurrent topics in Nathan C. Ihle's work include HER2/EGFR in Cancer Research (6 papers), Monoclonal and Polyclonal Antibodies Research (5 papers) and Chemical Synthesis and Analysis (3 papers). Nathan C. Ihle is often cited by papers focused on HER2/EGFR in Cancer Research (6 papers), Monoclonal and Polyclonal Antibodies Research (5 papers) and Chemical Synthesis and Analysis (3 papers). Nathan C. Ihle collaborates with scholars based in United States, Switzerland and Germany. Nathan C. Ihle's co-authors include Paul A. Wender, Carlos Roque D. Correia, Charles G. Cerveny, Michael Sun, Peter D. Senter, Kevin J. Hamblett, Stephen C. Alley, Michael Torgov, Richard S. Blackmore and Clayton H. Heathcock and has published in prestigious journals such as Journal of the American Chemical Society, Blood and Journal of Medicinal Chemistry.

In The Last Decade

Nathan C. Ihle

21 papers receiving 893 citations

Peers

Nathan C. Ihle
Bruce E. Tomczuk United States
Jin‐Cong Zhuo Switzerland
Milind Rajopadhye United States
Robert J. Cherney United States
Marcel Mueller Switzerland
Giulio Casi Switzerland
Mark D. Hylarides United States
Bruce E. Tomczuk United States
Nathan C. Ihle
Citations per year, relative to Nathan C. Ihle Nathan C. Ihle (= 1×) peers Bruce E. Tomczuk

Countries citing papers authored by Nathan C. Ihle

Since Specialization
Citations

This map shows the geographic impact of Nathan C. Ihle's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nathan C. Ihle with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nathan C. Ihle more than expected).

Fields of papers citing papers by Nathan C. Ihle

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nathan C. Ihle. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nathan C. Ihle. The network helps show where Nathan C. Ihle may publish in the future.

Co-authorship network of co-authors of Nathan C. Ihle

This figure shows the co-authorship network connecting the top 25 collaborators of Nathan C. Ihle. A scholar is included among the top collaborators of Nathan C. Ihle based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nathan C. Ihle. Nathan C. Ihle is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Bechtold-Peters, Karoline, Nathan C. Ihle, C. Lloyd Morgan, et al.. (2023). CMC Regulatory Considerations for Antibody-Drug Conjugates. Journal of Pharmaceutical Sciences. 112(12). 2965–2980. 14 indexed citations
2.
Ihle, Nathan C., Michael T. Jones, Kathleen A. Kelly, et al.. (2018). Control Strategy for Small Molecule Impurities in Antibody-Drug Conjugates. AAPS PharmSciTech. 19(3). 971–977. 18 indexed citations
3.
Shang, Xiao, Minh H. Nguyen, & Nathan C. Ihle. (2007). Stereochemical Assignments for All Four Isomers of Dolaproine via Lactam Formation. Synthesis. 2007(24). 3846–3850. 1 indexed citations
4.
Okeley, Nicole M., Stephen C. Alley, Charles G. Cerveny, et al.. (2006). Specific Tumor Targeting and Potent Bystander Killing with SGN-35, an Anti-CD30 Antibody Drug Conjugate.. Blood. 108(11). 231–231. 6 indexed citations
5.
Sun, Michael, Charles G. Cerveny, Kevin J. Hamblett, et al.. (2005). Reduction−Alkylation Strategies for the Modification of Specific Monoclonal Antibody Disulfides. Bioconjugate Chemistry. 16(5). 1282–1290. 294 indexed citations
6.
Hamblett, Kevin J., Jeremy Barton, Charles G. Cerveny, et al.. (2005). SGN-35, an Anti-CD30 Antibody-Drug Conjugate, Exhibits Potent Antitumor Activity for the Treatment of CD30+ Malignancies.. Blood. 106(11). 610–610. 13 indexed citations
7.
Cutshall, Neil S., et al.. (2002). Nicotinanilides as inhibitors of neutrophil chemotaxis. Bioorganic & Medicinal Chemistry Letters. 12(11). 1517–1520. 27 indexed citations
8.
Meißner, Robert, James J. Perkins, Le T. Duong, et al.. (2002). Nonpeptide αvβ3 antagonists. Part 2: constrained glycyl amides derived from the RGD tripeptide. Bioorganic & Medicinal Chemistry Letters. 12(1). 25–29. 38 indexed citations
9.
Cutshall, Neil S., et al.. (2001). Nicotinamide N -Oxides as CXCR2 antagonists. Bioorganic & Medicinal Chemistry Letters. 11(14). 1951–1954. 28 indexed citations
10.
Egbertson, Melissa S., Bohumil Bednář, Ben Askew, et al.. (2000). Nonpeptide GPIIB/IIIA receptor antagonists. Part 21: C-6 flexibility and amide bond orientation are important factors in determining the affinity of compounds for activated or resting platelet receptors. Bioorganic & Medicinal Chemistry Letters. 10(17). 1943–1948. 2 indexed citations
11.
Duggan, Mark E., Le T. Duong, John Fisher, et al.. (2000). Nonpeptide αvβ3 Antagonists. 1. Transformation of a Potent, Integrin-Selective αIIbβ3 Antagonist into a Potent αvβ3 Antagonist. Journal of Medicinal Chemistry. 43(20). 3736–3745. 68 indexed citations
12.
Ihle, Nathan C., et al.. (1996). Preparation of 4-Alkyl-2-[N-(tert-butoxycarbonyl)amino]pyridines by Alkylation, Nucleophilic Addition, and Acylation of 2-[N-(tert-Butoxycarbonyl)amino]-4-picoline1. The Journal of Organic Chemistry. 61(14). 4810–4811. 5 indexed citations
13.
Cook, Jacquelynn J., Marie A. Holahan, Denise Ramjit, et al.. (1996). Nonpeptide glycoprotein IIb/IIIa inhibitors. 8. Antiplatelet activity and oral antithrombotic efficacy of L-734,217.. Journal of Pharmacology and Experimental Therapeutics. 278(1). 62–73. 18 indexed citations
15.
DUGGAN, M. E., Adel M. Naylor-Olsen, James J. Perkins, et al.. (1995). ChemInform Abstract: Non‐Peptide Fibrinogen Receptor Antagonists. Part 7. Design and Synthesis of a Potent, Orally Active Fibrinogen Receptor Antagonist.. ChemInform. 26(51). 1 indexed citations
16.
Duggan, Mark E., Adel M. Naylor-Olsen, James J. Perkins, et al.. (1995). Non-Peptide Fibrinogen Receptor Antagonists. 7. Design and Synthesis of a Potent, Orally Active Fibrinogen Receptor Antagonist. Journal of Medicinal Chemistry. 38(17). 3332–3341. 56 indexed citations
17.
Barrett, Jeffrey S., Robert J. Gould, Joan D. Ellis, et al.. (1994). Pharmacokinetics and Pharmacodynamics of L-703,014, a Potent Fibrinogen Receptor Antagonist, After Intravenous and Oral Administration in the Dog. Pharmaceutical Research. 11(3). 426–431. 16 indexed citations
18.
Wender, Paul A., Nathan C. Ihle, & Carlos Roque D. Correia. (1988). Nickel-catalyzed intramolecular [4+4] cycloadditions. 4. Enantioselective total synthesis of (+)-asteriscanolide. Journal of the American Chemical Society. 110(17). 5904–5906. 122 indexed citations
19.
Wender, Paul A. & Nathan C. Ihle. (1987). Nickel-catalyzed intramolecular [4+4] cycloadditions: 2. Allylic stereoinduction and modelling studies in the preparation of bicyclo[6.4.0]dodecadienes. Tetrahedron Letters. 28(22). 2451–2454. 55 indexed citations
20.
Wender, Paul A. & Nathan C. Ihle. (1986). Nickel-catalyzed intramolecular [4 + 4]-cycloadditions: a new method for the synthesis of polycycles containing eight-membered rings. Journal of the American Chemical Society. 108(15). 4678–4679. 137 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026